Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Lipid or oil
Reexamination Certificate
2004-03-24
2010-11-23
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Lipid or oil
C424S184100, C424S204100, C424S234100, C424S278100, C424S093100, C435S235100, C435S243000
Reexamination Certificate
active
07838019
ABSTRACT:
Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
REFERENCES:
patent: 5676354 (1997-10-01), Okutsu et al.
patent: 5679354 (1997-10-01), Morein et al.
patent: 5753235 (1998-05-01), Haanes et al.
patent: 5925359 (1999-07-01), Van Woensel et al.
patent: 6177081 (2001-01-01), Wechter et al.
patent: WO 96/11711 (1996-04-01), None
patent: WO 2004/030696 (2004-04-01), None
Gupta et al., “Adjuvants—a balance between toxicity and adjuvanticity,” Vaccine, vol. 11 No. 3, pp. 293-306 (1993).
Lipford et al., “Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells,” Vaccine, vol. 12 No. 1, pp. 73-80 (Jan. 1994).
Stittelaar et al 2002, Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates. “Vaccine” vol. 21(3-4), Dec. 13, 2002, pp. 155-157, Available online Sep. 27, 2002.
van Binnendijk et al, 1997. Protective immunity in Macaques vaccinated with live attenuated recombinant and subunit vaccines in the presence of passively acquired antibodies. “J. Infect Diseases” vol. 175, pp. 524-532.
Sjolander et al. 2001. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte. “Vaccine” vol. 19(28-29), Jul. 16, 2001, pp. 4072-4080.
Pierre Tiollais, Christine Pourcel & Anne Dejean, “The Hepatitis B Virus”, Oct. 10, 1985, Nature, vol. 317, pp. 489-495.
P.G. W. Plagemann, “Hepatitis C Virus” Jun. 4, 1991, Arch Virol, vol. 120, pp. 165-180.
Karen Burke, Glynis Dunn, Morag Ferguson, Philip D. Minor, & Jeffrey W. Alamond, “Antigen Chimaeras of PolioVirus As Potential New Vaccines” Nature, vol. 332, Mar. 1998, (Abstract only).
Iosef, et al., Systemic and intenstinal antibody screening cell responses and protection in gnotobiotic pigs immunized orally with attenuated . . . , Vaccine 20 (2002) 1741-1753.
Yuan et al., Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus . . . , J. of Virology, Oct. 2001, 9229-9238.
Maria S. Di Genaro et al, Apr. 2003, “AttenuatedYersinia enterocoliticaMutant Strains Exhibit Differential Virulence in Cytokine-Deficient Mice: Implications for the Development of Novel Live Carrier Vaccines,” Infection and Immunity, American Society of Microbiology, vol. 71, Issue 4, pp. 1804-1812.
Rosemary E. Smith et al, 1999, “Immune-Stimulating Complexex Induce an IL-12Dependent Cascade on Innate Immune Responses,” The Journal of Immunologym, 162, pp. 5536-5546.
Harold F. Stills, Jr., 2005, “Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund's complete and Other Adjuvants,” ILAR Journal, vol. 46, Issue 3, pp. 280-293.
Yifan Zhan et al., 1998, “Control of IL-12 and IFN-y Production in Response to Live or Dead Bacteria by TFN and Other Factors,” The Journal of Immunology, 161, pp. 1447-1453.
Sigma Product Information; techserv@sial.com; Saponin From Quillaja Bark Purified; Sigma Prod. No. S4521; Case No. 8047-15-2; Oct. 25, 1996; pp. 1-3.
Hu, Ke-Fei et al., Immunostimulating Complexes (ISCOMs) for Nasal Vaccination; Elsevier Science B.V. Advanced Drug Delivery Reviews 51 (2001) pp. 149-159.
The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; Committee for Proprietary Medicinal Products, Note for Guidance on Pharmaceutical and Biological Aspects of Combined Vaccines; London, Jul. 23, 1998 pp. 1-14.
The European Medicines Agency, Evaluation of Medicines for Human Use; Committee for Medicinal Products for Human Use, Guideline on Adjuvants in Vaccines for Human Use; London, Jan. 20, 2005 pp. 1-18.
Morein, B, et al.; Iscom, A Novel Structure for Antigenic Presentation of Membrane Proteins from Enveloped Viruses; Nature, vol. 308, No. 5958, Mar. 29, 1984; pp. 457-460; Macmillan Journals Ltd., 1984.
Takahashi, Hidemi et al.; Induction of CD8 Cytotoxic T cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs; Nature, vol. 344, Apr. 26, 1990; pp. 873-875.
Chavali S., et al., An In Vitro Study of Immunomodulatory Effects of Some Saponins; International Society for Immunopharmacology, vol. 9, No. 6, Mar. 24, 1987, Great Britain, pp. 675-683.
Chavali S., et al., Adjuvant Effects of Orally Administered Saponins on Humoral and Cellular Immune Responses in Mice; Immunobiol., vol. 174, Mar. 2, 1987, pp. 347-359.
Roner, Michael R., et al., Antiviral Activity Obtained from Aqueous Extracts of the Chilean Soapbark Tree (Quillaja Saponaria Molina); Journal of General Virology, 2007, vol. 88, pp. 275-285.
Rajput, Zahid Iqbal et al., Adjuvant Effects of Saponins on Animal Immune Responses; Journal of Zhejiang University Science B, 2007 vol. 8 (3) pp. 153-161.
Vaccine Development Overview; http://www.brown.edu/Courses/Bio—160/Projects1999/vaccineoverview, Jun. 16, 2009; pp. 1-5.
Initiative for Vaccine Research, Live Attenuated Vaccines; World Health Organization, 2009, p. 1.
BCCDC Laboratory Services; A Guide to Selection and Use of Disinfectants; BC Centre for Disease Control, 2003, pp. 1-18.
Francis, George, et al., The Biological Action of Saponins in Animal Systems: A Review; British Journal of Nutrition (2002), vol. 88, pp. 587-506; The Authors 2002.
www.patentstorm.us/patents/6177081/description.html; Human and Marmoset Activation Viruses- US Patent 6177081.
Sparg, S.G., et al. Biological Activities and Distribution of Plant Saponins; Journal of Ethno-Pharmacology; www.elsevier.com/locate/jethpharm; vol. 94 (2004), pp. 219-243.
Barr, Ian G., et al., ISCOMs (immunostimulating complexes): The first decade; CSL Limited, Parkville, Victoria Australia; Immunology and Cell Biology (1996) vol. 74, pp. 8-25.
Incorporation and live iscom—PubMed Results; http://www.ncbi.nlm.nih.gov/sites/entrez; Jun. 14, 2009, pp. 1-16.
Iscom—PubMed Results; http://www.ncbi.nlm.nih.gov/sites/entrez, Jun. 14, 2009, pp. 1-3.
Incorporation and iscom—PubMed Results; http://www.ncbi.nlm.nih.gov/sites/entrez, Jun. 14, 2009, pp. 1-3.
Viruses, Bacterial and Fungi, Sizes and Significance; Ion Life, http://www.ionizers.org; Jun. 16, 2009, pp. 1-4.
Fohlman, Jan et al., Vaccination of Balb/c mice against enteroviral mediated myocarditis; Vaccine, vol. 8, Aug. 1990; Butterworth-Heinemann Ltd; pp. 381-384.
Bengtsson Karin Lovgren
Morein Bror
Isconova AB
Lucas Zachariah
Pearne & Gordon LLP
LandOfFree
Composition comprising iscom particles and live micro-organisms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising iscom particles and live micro-organisms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising iscom particles and live micro-organisms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159097